Thank you misiu! That is what I thought, but wasn’t 100% sure. I would think it is unlikely that mono gets early approval (before completion of pivotal trial), but I would think that all sBLAs will be quicker as the primary changes will only be in the clinical results portion of the BLA (CMO and non-clinical should be well resolved in the combo BLA).
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.